Get the Stockscreener App
7.42
2.20%
0.16
After Hours:
7.47
0.05
+0.67%
Atara Biotherapeutics Inc stock is traded at $7.42, with a volume of 55,246.
It is up +2.20% in the last 24 hours and up +32.74% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
See More
Previous Close:
$7.26
Open:
$7.24
24h Volume:
55,246
Relative Volume:
0.87
Market Cap:
$45.07M
Revenue:
$100.44M
Net Income/Loss:
$-133.16M
P/E Ratio:
-0.288
EPS:
-25.76
Net Cash Flow:
$-94.85M
1W Performance:
-1.85%
1M Performance:
+32.74%
6M Performance:
-34.39%
1Y Performance:
-47.52%
1-Day Range:
$6.90
$7.615
1-Week Range:
$6.90
$8.65
52-Week Range:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
7.42 | 45.07M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.67 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
569.12 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.35 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.94 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
FDA lifts clinical hold on Atara’s Ebvallo - The Pharma Letter
FDA Lifts Hold on Atara’s EBVALLO Program - TipRanks
Atara Does An About Face As FDA Lifts Ebvallo Hold - insights.citeline.com
(ATRA) Investment Analysis - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth - simplywall.st
FDA Lifts Hold on Atara Biotherapeutics' Ebvallo Program | ATRA Stock News - GuruFocus
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) | ATRA Stock News - GuruFocus
Atara Biotherapeutics Says FDA Lifts Clinical Hold Enabling Resumption Of Clinical Trials - marketscreener.com
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) - Business Wire
Atara Biotherapeutics, Inc. Provides Regulatory Updates on EBVALLO?? (Tabelecleucel) - marketscreener.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Acquired by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Head-To-Head Contrast: Atara Biotherapeutics (NASDAQ:ATRA) and Creative Medical Technology (NASDAQ:CELZ) - Defense World
(ATRA) On The My Stocks Page - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech
Layoff Tracker: Spark Lays Off 298 Employees - BioSpace
Atara Biotherapeutics stock hits 52-week low at $5.3 - Investing.com
Atara Biotherapeutics stock hits 52-week low at $5.3 By Investing.com - Investing.com UK
How the (ATRA) price action is used to our Advantage - news.stocktradersdaily.com
Atara Biotherapeutics IncOn March 31, Entered Amendment To Commercialization Agreement With Pierre FabreSEC Filing - marketscreener.com
Epstein-Barr Virus (EBV) Market Growth 2025: Trends, Consumer - openPR.com
Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes - MSN
Long Term Trading Analysis for (ATRA) - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Atara Biotherapeutics (NASDAQ:ATRA) Stock Crosses Below 50 Day Moving Average – Should You Sell? - Defense World
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail
(ATRA) Investment Report - news.stocktradersdaily.com
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group - Defense World
Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement - TipRanks
SNOA's Wound Care Products Get Regulatory Clearance, LFMD's Q4 Revenue Soars, ATRA On Watch - RTTNews
Atara Biotherapeutics: Q4 Earnings Snapshot - The Bakersfield Californian
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Atara Biotherapeutics Reports 2024 Financial Results - TipRanks
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics Inc. (ATRA) reports earnings - Quartz
Atara Biotherapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop - Simply Wall St
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.73%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):